Belite Bio, Inc
NASDAQBelite Bio has cleared its Q1 earnings hurdle but the stock has not stopped falling — down 10% on the week to $139.70, extending a 16% one-month retreat that predates the print. The Q1 result itself delivered the familiar pattern. The stock fell 2.6% on earnings day and has lost 8.3% over the subsequent five sessions, matching almost exactly the trajectory after the March 2 print…
BLTE short interest surges 33.2% in one week to 1.23M shares as cost to borrow jumps 86% to 1.54%. Availability remains exceptionally high at 1,279%, suggesting ample shares for shorting despite rising borrowing costs ahead of earnings.
Snapshot as of 20 May 2026
Belite Bio has cleared its Q1 earnings hurdle but the stock has not stopped falling — down 10% on the week to $139.70, extending a 16% one-month retreat that predates the print. The Q1 result itself delivered the…
BLTE heads into tomorrow's Q1 earnings with short sellers building positions aggressively — and a stock that has given back nearly 17% in a month. The sharpest signal heading into the May 20 report is the jump in short…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BLTE — free to start on ORTEX.
Sign up for free →Open BLTE on ORTEX